stockrowADMA Biologics Inc
ADMA Healthcare Biotechnology
ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024.
- Revenue
- +5.12%
- EPS
- +46.7%
- Free cash flow
- +1,709.5%
- Total debt
- +140.5%
Quarter to September 2026, against a year earlier
Follow ADMA
Alert me
ADMA Biologics Inc (ADMA) Net income
ADMA Biologics Inc's net income for fiscal 2025 was $146.9M, down 25.7% from $197.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was $182.4M. Over the past ten years it has ranged from −$75.7M (fiscal 2020) to $197.7M (fiscal 2024); the current reading is higher than 91% of that period. ADMA Biologics Inc ranks 24th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $146.9M | (25.67%) |
| FY2024 | $197.7M | — |
| FY2023 | −$28.2M | — |
| FY2022 | −$65.9M | — |
| FY2021 | −$71.6M | — |
| FY2020 | −$75.7M | — |
| FY2019 | −$48.3M | — |
| FY2018 | −$65.7M | — |
| FY2017 | −$43.8M | — |
| FY2016 | −$19.5M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $49.9M | 31.89% |
| Jun 2026 | $37.8M | (16.56%) |
| Mar 2026 | $45.3M | (8.20%) |
| Dec 2025 | $49.4M | 35.55% |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $314.3M |
| ADMA ADMA Biologics Inc | $182.4M |
| VCEL Vericel Corporation compare | $33.3M |
| PVLA Palvella Therapeutics, Inc. compare | −$61.7M |
| PHVS Pharvaris N.V. compare | −$193.1M |
| IMNM Immunome, Inc. compare | −$254.3M |
| CLDX Celldex Therapeutics, Inc. compare | −$300.5M |
| VERA Vera Therapeutics, Inc. compare | −$401.9M |
| BHVN Biohaven Ltd. compare | −$542.7M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on ADMA
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement